Search Technologies

NCI's Surgery Branch seeks partners interested in licensing or co-developing a T cell therapy for treating KRAS mutant positive cancers.

Researchers at the National Cancer Institute (NCI) have developed an invention consisting of hydrocarbon stapled peptides that disrupt the linear ubiquitin-chain assembly complex (LUBAC), which is involved in NF-κB signaling. These peptides can be used as a therapeutic in the treatment of the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), a type of non-Hodgkin’s lymphoma, as well as inflammatory diseases. The NCI seeks licensing and/or co-development research collaborations for inhibitors of NF-κB signaling and/or treatment of ABC DLBCL, as well as inflammatory diseases.

Novel class of anti-HIV compounds that inhibit viral recognition process and nuclear export activity.

The National Cancer Institute (NCI) Molecular Targets Laboratory is seeking parties interested in collaborative research to co-develop antiviral tropolone derivatives developed by systematic medicinal chemistry on the lead series.

The National Cancer Institute Laboratory of Molecular Biology seeks parties to license or co-develop and commercialize antibody drug/toxin conjugates as liver cancer therapy and diagnostics.

The National Cancer Institute, Chemical Biology Laboratory is seeking parties interested in licensing NO-releasing polymers for commercial applications in wound healing.

Researchers at the National Cancer Institute, Laboratory of Molecular Immunoregulation developed compositions and methods for using HMGN and its derivatives as immunoadjuvants with microbial or tumor antigens.The National Cancer Institute, Laboratory of Molecular Immunoregulation seeks parties interested in licensing or collaborative research to co-develop polypeptides or antagonists for immune response regulation.

RNA interference (RNAi) is a naturally occurring cellular post-transcriptional gene regulation process that utilizes small double-stranded RNAs to trigger and guide gene silencing. By introducing synthetic RNA duplexes called small-interfering RNAs (siRNAs), we can harness the RNAi machinery for therapeutic gene control and the treatment of various diseases. The National Cancer Institute seeks partners to license or co-develop RNA, RNA-DNA, and DNA-RNA hybrid nanoparticles consisting of a DNA or RNA core with attached RNA or DNA hybrid duplexes.

The National Cancer Institute is seeking parties interested in collaborative research to co-develop or license the in vitro and in vivo removal of targets using light energy.